



01997.022600.

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	:	Examiner: Unassigned
WEI LIU, ET AL.	)	
	:	Group Art Unit: Unassigned
Appln. No.: 10/671,740	)	
	:	
Filed: September 29, 2003	)	
	:	
For: CELL SURFACE MOLECULES AS	)	
MARKERS AND THERAPEUTIC	:	
AGENTS AGAINST KIDNEY	)	
CANCERS	:	February 20, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

Applicants request that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be initialed and returned, indicating that such information has been considered.

No fee is believed to be due in connection with the filing of this Information Disclosure Statement. Nevertheless, the Commissioner is authorized to charge any fees deemed to be due, or credit any overpayment, to Deposit Account No. 06-1205.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.


Respectfully submitted,

  
Lawrence S. Perry  
Registration No. 31,865  
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200


NMD/ksp

DC\_MAIN 119801v1

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				ATTY DOCKET NO. <b>01997.022600</b>		APPLICATION NO. <b>10/671,740</b>	
				APPLICANT <b>WEI LIU, ET AL.</b>			
				FILING DATE <b>September 29, 2003</b>		GROUP <b>Unassigned</b>	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,970,198	11/13/90	Lee, et al.	514	25	
		5,079,233	01/07/92	Lee	514	25	
		5,573,924	11/12/96	Beckman, et al.	435	69.5	
		5,585,089	12/17/96	Queen, et al.	424	133.1	
		5,606,040	02/25/97	McGahren, et al.	536	17.6	
		5,693,762	12/19/97	Queen, et al.	530	387.3	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Arens, Ramon, et al., "Constitutive CD 27/CD70 interaction induces expansion of effector-type Tcells and results in IFN $\gamma$ -mediated B cell depletion", Immunity 15, pp. 801-812 (November 2001).					
		Blanchard AP, Hood L., "Sequence to array: probing the genome's secrets", Nat. Biotech 1996 Dec; 14(13); p. 1649 (PMID 9634840).					
		Blass-Kampmann, S., et al., "gp130RB13-6-positive neural progenitor cells are susceptible to the oncogenic effect of ethylnitrosourea in pre-natal rat brain", Neuropathol. Appl. Neurobiol. 24(1): pp. 9-20 (Feb. 1998) (Abstract).					
		Bollen, M., et al., "Nucleotide pyrophosphatases/phosphodiesterases on the move," Crit. Rev. Biochem. Mol. Biol., 35(6), pp. 393-432 (2000).					
		Bowman, M.R., "The cloning of CD70 and its identification as the ligand for CD27", J. Immunol., 152(4), pp. 1756-1761 (Feb. 15, 1994).					
		Bühring, Hans-Jörg, et al., "The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3", Vol. 97 (10), pp. 3303-3305 (May 2001).					
		Camerini, D., et al., "The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family", J. Immunol., 147, pp. 3165-3169 (1991).					
EXAMINER				DATE CONSIDERED			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NMD/ksp

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				ATTY DOCKET NO. <b>01997.022600</b>		APPLICATION NO. <b>10/671,740</b>	
				APPLICANT <b>WEI LIU, ET AL.</b>			
				FILING DATE <b>September 29, 2003</b>		GROUP <b>Unassigned</b>	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,739,116	04/14/98	Hamann, et al.	514	25	
		5,767,285	06/16/98	Hamann, et al.	548	542	
		5,773,001	06/30/98	Hamann, et al.	424	181.1	
		6,185,561 B1	02/06/01	Balaban, et al.	707	6	
		6,506,559 B1	01/14/03	Fire, et al.	435	6	
		6,573,099 B2	06/03/03	Graham	435	455	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Couderc, B., et al., "Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells", Cancer Gene Ther. 5, pp. 163-175, (1998), (Abstract).					
		Deissler, H., et al., "Neural cell surface differentiation antigen gp130 <sup>RB13-6</sup> induces fibroblasts and glioma cells to express astroglial proteins and invasive properties", FASEB J. 13: pp. 657-666, (April 1999).					
		Ferguson, JA., et al., "A fiber-optic DNA biosensor microarray for the analysis of gene expression", Nat. Biotech 14 (13): pp. 1681-1684 PMID 9634851 (December, 1996).					
		Geiseg, M., et al., "Expression profiling of human renal carcinomas with functional taxonomic analysis", BMC Bioinformatics 3:26, (September 30, 2002).					
		GeneChip® 3.1 Expression Analysis Algorithm Tutorial Manual found in the Affymetrix GeneChip® Expression Analysis Manual.					
		Goodwin, R., et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor", Cell 73, pp. 447-456, (May, 1993).					
		Gravestien, L.A., et al., "Cloning and expression of murine CD27: comparison with 4-1BB, another lymphocyte-specific member of the nerve growth factor receptor family", Eur. J. Immunol. 23, pp. 943-950 (1993).					
		Hamann, PR., et al., "Gemtuzumab ozogamicin, a potent and selective antiCD33 anti-body-calicheamicin conjugate for treatment of acute myeloid leukemia", Bioconj Chem 2002 Jan-Feb; (1) pp. 47-58.					
		Hannon, Gregory J., "RNA Interference", Nature 418, pp. 244-251 (July 11, 2002).					
EXAMINER				DATE CONSIDERED			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				ATTY DOCKET NO. <b>01997.022600</b>		APPLICATION NO. <b>10/671,740</b>	
				APPLICANT <b>WEI LIU, ET AL.</b>			
				FILING DATE <b>September 29, 2003</b>			GROUP <b>Unassigned</b>
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		2002/0173478A1	11/21/02	Gerwitz	514	44	
		2003/0108923 A1	06/12/03	Tuschl, et al.	435	6	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Hendriks, Jenny, et al., "CD27 is required for generation and long-term maintenance of T cell immunity", Nature Immunol. 1(5), pp. 433-440, (November, 2000).					
		Hill, Andrew A., et al., "Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls", Genome Biol. 2001 2(12), research, pp. 0055.1-0055.13, (November, 2001).					
		Hishima, T., et al., "CD70 expression in thymic carcinoma", Am. J. Surg. Pathol. 24(5), pp. 742-746, (May, 2000), (Abstract).					
		Israel, Bruce F., et al., "Enhancement of adenovirus vector entry into CD-70-positive B-cell lines by using a bispecific CD70-adenovirus fiber antibody", J. Virol. 75(11), pp. 5215-5221, (June, 2001).					
		Jin-Hua, P., et al., "Molecular cloning and chromosomal localization of PD-IB (PDNP3), a new member of the human phosphodiesterase I genes", Genomics 45(2), pp. 412-415 (1997).					
		Kelly, Janice M., et al., "Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection", Nature Immunol. 3(1), pp. 83-90, (January, 2002).					
		Lens, Susanne, M.A., et al., "CD27-CD70 Interaction: Unravelling its Implication in Normal and Neoplastic B-Cell Growth", Leukemia and Lymphoma 18, pp. 51-59, (1995).					
		Lens, Susanne M.A., et al., "Control of lymphocyte function through CD27-CD70 interactions", Sem. In Immun. 10(6), pp. 491-499, (December 1998).					
		Lockhart, David J., et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays", Nature Biotechnol. 14, pp. 1675-1680 (December, 1996).					
		Lorenz, M.G., et al., "Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70" (CD27L), Hum. Gene Ther. 10(7), pp. 1095-1103, (May, 1999). (Abstract).					
EXAMINER				DATE CONSIDERED			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 ( <i>modified</i> )  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		ATTY DOCKET NO. <b>01997.022600</b>	APPLICATION NO. <b>10/671,740</b>				
		APPLICANT <p style="text-align: center;"><b>WEI LIU, ET AL.</b></p>					
		FILING DATE <b>September 29, 2003</b>	GROUP <b>Unassigned</b>				
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Nakajima, Atsuo, et al., "Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis", J. Neuroimmunol. 109, pp. 188-196, (2000).					
		Oshima, Hideo, et al., "Characterization of murine CD70 by molecular cloning and mAb", Int'l Immunol. 10(4), pp. 517-526, (1998).					
		Scherr, Michaela, et al., "Gene silencing mediated by small interfering RNAs in mammalian cells", Current Medicinal Chemistry 10; pp. 245-256 (2003).					
		Shapiro, C., et al., "Chapter 117 - Tumors of the Kidney, Ureter and Bladder", in <u>Goldman: Cecil Textbook of Medicine</u> , 21 <sup>st</sup> edition, W.B. Saunders Company, p. 631, <i>et. seq.</i> (2000).					
		Simons, Jonathan W., et al., "Chapter 66 - Kidney and Ureter", in <u>Abeloff: Clinical Oncology</u> , 2 <sup>nd</sup> edition, Churchill Livingstone, Inc., p. 1784, <i>et. seq.</i> (2000).					
		Takahashi, et al., "Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification", 98(17) Proc. Nat'l Acad. Sci. , pp. 9754-9759 (August 14, 2001). <i>See also</i> supplemental material for this article. (August 7, 2001) Proc. Natl. Acad. Sci. USA 10.1073/pnas, 1712099998.					
		Tesselaar, Kiki, et al., "Characterization of Murine CD70, the Ligand of the TNF Receptor Family Member CD27", J. Immunol. 159, pp. 4959-4965, (1997).					
EXAMINER				DATE CONSIDERED			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				ATTY DOCKET NO. <b>01997.022600</b>		APPLICATION NO. <b>10/671,740</b>	
				APPLICANT <b>WEI LIU, ET AL.</b>			
				FILING DATE <b>September 29, 2003</b>			GROUP <b>Unassigned</b>
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		LocusLink, TNFSF7: "TNFSF7: tumor necrosis factor (ligand) superfamily, member 7", (Locus) obtained from NCBI sequence viewer available at <a href="http://www.ncbi.nlm.nih.gov">http:// www.ncbi.nlm.nih.gov</a> .					
		Entrez Protein, "P26842 CD27L receptor precursor (t-cell activation antigen CD27) (T14)". (Locus) obtained from NCBI sequence viewer available at <a href="http://www.ncbi.nlm.nih.gov">http:// www.ncbi.nlm.nih.gov</a> .					
		Entrez Nucleotide, "XM_011540 homo sapiens ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3), mRNA". (Locus) obtained from NCBI sequence viewer available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .					
		Entrez Nucleotide, "NM_001252 homo sapiens tumor necrosis factor (ligand) superfamily, member 7 (TNFSF7), mRNA. (Locus) obtained from NCBI sequence viewer available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .					
		Entrez Nucleotide, "NM_005021 homo sapiens ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3), mRNA. (Locus) obtained from NCBI sequence viewer available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .					
		Entrez Nucleotide, "BG420391 602452420F1 NIH_MGC_14 Homo sapiens cDNA clone IMAGE: 4590773 5' mRNA sequence". (Locus) obtained from NCBI sequence viewer available at <a href="http://www4.ncbi.nlm.nih.gov">http://www4.ncbi.nlm.nih.gov</a> .					
		Entrez Nucleotide, "L08096 Human CD27 ligand mRNA, complete cds". (Locus) obtained from NCBI sequence viewer available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .					
		UniGene Cluster Hs.99899, "TNFSF7 tumor necrosis factor (ligand) superfamily, member 7". (Locus) obtained from NCBI UniGene available at <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> .					
EXAMINER				DATE CONSIDERED			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				ATTY DOCKET NO. <b>01997.022600</b>		APPLICATION NO. <b>10/671,740</b>	
				APPLICANT <b>WEI LIU, ET AL.</b>			
				FILING DATE <b>September 29, 2003</b>		GROUP <b>Unassigned</b>	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		<b>InvivoGen, "Intronless Genes - CD70/CD27L/TNFSF - Co-stimulatory genes" at  <a href="http://www.invivogen.com/genedescription/cd70.htm">http://www.invivogen.com/genedescription/cd70.htm</a>. Visited on 3/19/02.</b>					
		<b>E-NPP3 (CD203c) "Protein Reviews on the Web" (Locus) obtained from PROW Guide available at  <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a>.</b>					
		<b>E-NPP3 (CD70) "Protein Reviews on the Web" (Locus) obtained from PROW Guide available at  <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a>.</b>					
		<b>GeneChip® Human Genome U95 Set found in the Affymetrix Manual.</b>					
		<b>Product Labelling Information for Mylotarg® (gemtuzumab ozogamicin for injection),  <a href="http://www.Wyeth.com">http://www.Wyeth.com</a>.</b>					
EXAMINER				DATE CONSIDERED			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 6 of 6

NMD/ksp